Aspirin Zinc

A UV-Vis spectrophotometric method enhanced by chemometric techniques, specifically Principal Component Regression (PCR) and Partial Least Squares (PLS) regression, was developed and validated for the simultaneous quantification of prasugrel (PRA) and aspirin (ASP) in bulk drugs and pharmaceutical formulations. The method demonstrated high accuracy, precision, and robustness, achieving mean recoveries of 100.63% for PRA and 100.08% for ASP with relative standard deviations (RSD) below 3%. Both PCR and PLS models showed excellent predictive capabilities, with RMSEP values of 0.45-0.48 for PRA and 0.78-1.13 for ASP, indicating the models' reliability. In line with green and white chemistry principles, the method minimizes environmental impact by reducing solvent consumption and waste generation compared to traditional chromatographic methods. The Analytical Eco-Scale score was 84, reflecting excellent compliance with green chemistry standards. The method's simplicity, low energy consumption, and reduced chemical waste further support its alignment with sustainability goals. However, acetonitrile, a hazardous solvent, was still used in small quantities, and solvent recycling was not implemented, slightly affecting the eco-score. To evaluate the method's greenness, the RGB12 algorithm was applied, achieving a high score of 94.4%, with the majority of parameters related to reagent consumption, waste production, energy efficiency, and safety scoring optimally. The method's safety, cost-effectiveness, and minimal environmental footprint make it suitable for routine pharmaceutical analysis, particularly in quality control environments where resource efficiency and sustainability are prioritized. Thus, the developed method offers a sustainable, efficient, and environmentally friendly solution for the simultaneous analysis of prasugrel and aspirin in pharmaceutical formulations, making it a valuable tool for routine analysis in the pharmaceutical industry.

To determine the impact of low-dose aspirin (81 mg) on markers of maternal inflammation and placental function.

Rural Southern India.

Nulliparous women with a singleton pregnancy dated by ultrasound who were enrolled in the ASPIRIN (Aspirin Supplementation for Pregnancy Indicated risk Reduction In Nulliparas) Trial.

We performed a case-control study to elucidate the impact of low dose aspirin (LDA) on markers of placental function and maternal inflammation among women who delivered prematurely compared to term controls in women enrolled in the ASPIRIN trial. Women were prospectively enrolled in an ancillary observational trial wherein maternal serum was collected and measured between 10 to 13 weeks and 17 to 21 weeks of gestation after initiation of aspirin or an identical placebo.

From 2016-18 with a total of 666 n women enrolled in this ancillary trial of whom 269 were selected for analyte analysis. Women who received LDA had lower levels of Alpha Feto-Protein (AFP) at 10 to 13 weeks than women who received placebo (Placebo) (LDA 18.3 ng/mL vs 21.4 ng/mL -P 0.001). AFP was similar between the two groups at 17 to 21 weeks. No other differences were seen in C-Reactive protein or Anti-Mullerian Hormone.

Low-dose aspirin administration lowers AFP early in pregnancy.